

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 March 2024 (21.03.2024)



(10) International Publication Number
WO 2024/059739 A1

(51) International Patent Classification:
C07K 16/08 (2006.01) *A61P 25/28* (2006.01)
C07K 16/18 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2023/074239

(22) International Filing Date:
14 September 2023 (14.09.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/406,924 15 September 2022 (15.09.2022) US
63/448,913 28 February 2023 (28.02.2023) US

(71) Applicant: **VOYAGER THERAPEUTICS, INC.**
[US/US]; 75 Hayden Ave., Lexington, Massachusetts 02421
(US).

(72) Inventors: **LIU, Wencheng**; c/o Voyager Therapeutics,
Inc., 75 Hayden Ave., Lexington, Massachusetts 02421
(US). **CARTER, Todd**; c/o Voyager Therapeutics, Inc.,
75 Hayden Ave., Lexington, Massachusetts 02421 (US).
SHAH, Ishan Sanjeev; c/o Voyager Therapeutics, Inc.,
75 Hayden Ave., Lexington, Massachusetts 02421 (US).
MURRAY, Christopher Joseph; 111 Colinvale, Pole-
glass, BT17 0JW (IE). **MCCLORY, James Bernard**;
42 Bronte, Banbridge, County Down, Ballynaskeagh,
BT325BS (IE). **SAH, Dinah Wen-Yee**; 15 Huckleberry
Road, Hopkinton, Massachusetts 01748 (US).

(74) Agent: **POTI, Kristin** et al.; K&L Gates LLP, 1 Congress
Street, Suite 2900, Boston, Massachusetts 02114 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2024/059739 A1

(54) Title: TAU BINDING COMPOUNDS

(57) Abstract: The present disclosure provides anti-tau antibodies and vectorization thereof (e.g., into AAV particles). Also provided are methods of using anti-tau antibodies and/or AAV particles for prevention, treatment, and/or diagnosis of neurological indications.